NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

AURA

Aura Biosciences Inc

May 23 • 04:00PM ET

5.89

Dollar change -0.05
Percentage change -0.84	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT FATE ARVN ITCI KURA RVNC MEIP

| Held by: IWM VTI VXF IWN IBB VTWO IWC DFAS ITOT AVSC

Index	RUT	P/E	-	EPS (ttm)	-1.90	Insider Own	12.38%	Shs Outstand	62.00M	Perf Week	-1.01%
Market Cap	365.21M	Forward P/E	-	EPS next Y	-1.94	Insider Trans	0.22%	Shs Float	54.33M	Perf Month	6.70%
Income	-94.70M	PEG	-	EPS next Q	-0.47	Inst Own	61.10%	Short Float	3.98%	Perf Quarter	-20.08%
Sales	0.00M	P/S	-	EPS this Y	-14.93%	Inst Trans	-8.03%	Short Ratio	7.43	Perf Half Y	-33.97%
Book/sh	2.55	P/B	2.31	EPS next Y	3.62%	ROA	-48.51%	Short Interest	2.16M	Perf Year	-15.25%
Cash/sh	2.06	P/C	2.85	EPS next 5Y	0.15%	ROE	-56.24%	52W Range	4.34 - 12.38	Perf YTD	-28.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.09%	ROI	-66.11%	52W High	-52.42%	Beta	0.43
Dividend TTM	-	Quick Ratio	11.06	Sales past 5Y	0.00%	Gross Margin	-	52W Low	35.56%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	11.06	EPS Y/Y TTM	-1.91%	Oper. Margin	-	RSI (14)	52.90	Volatility	0.59% 6.65%
Employees	106	Debt/Eq	0.14	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.00
Option/Short	Yes / Yes	LT Debt/Eq	0.12	EPS Q/Q	-37.59%	Payout	-	Rel Volume	0.54	Prev Close	5.94
Sales Surprise	-	EPS Surprise	-12.02%	Sales Q/Q	-	Earnings	May 15 BMO	Avg Volume	291.22K	Price	5.89
SMA20	4.44%	SMA50	-0.02%	SMA200	-25.87%	Trades		Volume	158,183	Change	-0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-24	Initiated	H.C. Wainwright	Buy	$21
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Apr-17-23	Resumed	BTIG Research	Buy	$38
Jul-19-22	Initiated	JMP Securities	Mkt Outperform	$26

May-15-25 09:32AM	Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire) +5.71%
06:10AM	Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
06:01AM	Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-01-25 04:01PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-06-25 04:35PM	Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential? (Insider Monkey)
07:00AM	Loading…
Apr-02-25 07:00AM	Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors (GlobeNewswire)
Mar-25-25 06:58PM	Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript) (SeekingAlpha) -15.40%
Mar-24-25 04:01PM	Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) -6.67%
07:00AM	Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress (GlobeNewswire)
Mar-03-25 07:00AM	Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress (GlobeNewswire)
Feb-25-25 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-26-24 08:00AM	Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-12-24 04:05PM	Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Oct-17-24 04:05PM	Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial (GlobeNewswire) +14.09%
Sep-12-24 06:30AM	Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma (GlobeNewswire) +7.94%
04:05PM	Loading…
Sep-03-24 04:05PM	Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 (GlobeNewswire) -7.04%
Aug-28-24 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-24 04:05PM	Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting (GlobeNewswire)
Aug-08-24 07:00AM	Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-06-24 09:55AM	Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High? (Zacks)
May-30-24 04:05PM	Aura Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 08:00AM	Aura Biosciences to Host Virtual KOL Event Pioneering a New Standard of Care In Ocular Oncology on May 29, 2024 (GlobeNewswire)
May-10-24 02:58PM	Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:55PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-08-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-27-24 01:53PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-26-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
09:55AM	Loading…
Dec-11-23 09:55AM	Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet (Zacks) -8.46%
Dec-07-23 08:00AM	Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma (Business Wire)
Nov-23-23 09:55AM	Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade (Zacks)
Nov-09-23 04:05PM	Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +9.54%
Nov-08-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-23 10:02PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -8.18% -32.55%
04:08PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
03:00PM	Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma (Business Wire)
Oct-31-23 04:05PM	Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 (Business Wire) +9.24% +9.93%
Oct-02-23 04:05PM	Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments (Business Wire) -7.47%
Aug-09-23 07:00AM	Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -6.62%
Jul-31-23 06:07AM	Owning 38% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), (Simply Wall St.)
May-24-23 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire) -5.29%
May-12-23 07:00AM	Aura Biosciences to Participate in the JMP Securities Life Sciences Conference (Business Wire)
May-11-23 04:10PM	Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
May-03-23 07:52AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Mar-15-23 04:10PM	Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
11:11AM	Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-16-23 10:43AM	Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate (Benzinga) -7.17%
07:00AM	Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration (Business Wire)
Feb-10-23 06:03AM	Why Shares of Aura Biosciences Jumped This Week (Motley Fool)
Feb-09-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-24-22 09:27AM	Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year losses (Simply Wall St.)
Dec-16-22 09:54AM	12 Stocks Insiders are Buying Now (Insider Monkey)
Nov-30-22 08:50PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -6.02%
04:01PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-24-22 06:34AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Nov-10-22 07:00AM	Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
06:45AM	Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma (Business Wire)
Nov-03-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Oct-06-22 10:12AM	Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation (Simply Wall St.)
Oct-04-22 07:05AM	Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform (GlobeNewswire)
Oct-03-22 01:37PM	Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug (Benzinga) -19.48%
07:00AM	Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 (Business Wire)
Sep-28-22 07:00AM	Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire) +19.23%
Sep-27-22 07:00AM	Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 (Business Wire) +5.12%
Sep-07-22 07:00AM	Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress (Business Wire)
Sep-01-22 07:00AM	Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress (Business Wire)
Aug-11-22 04:15PM	Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -8.60% +8.89%
Aug-02-22 07:00AM	Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference (Business Wire)
Jul-19-22 03:04PM	JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer" (Benzinga) +7.67%
Jul-17-22 08:36AM	Could The Aura Biosciences, Inc. (NASDAQ:AURA) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jun-30-22 08:51AM	Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate (MarketWatch) +12.73%
07:00AM	Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire)
Jun-23-22 08:44AM	Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer (Benzinga) -6.00%
Jun-22-22 04:30PM	Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma (Business Wire)
Jun-17-22 07:00AM	Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting (Business Wire) +6.92%
06:40AM	Bullish Aura Biosciences, Inc. (NASDAQ:AURA) investors are yet to receive a pay off on their US$716k bet (Simply Wall St.)
May-26-22 05:26PM	Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting (Business Wire)
May-25-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
May-12-22 04:15PM	Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +5.82%
May-03-22 04:05PM	Aura Biosciences Presents Preclinical Data Highlighting AU-011s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting (Business Wire)
07:00AM	Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference (Business Wire)
Apr-29-22 07:53AM	We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth (Simply Wall St.) +6.33%
Mar-23-22 04:15PM	Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
Mar-21-22 07:00AM	Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma) (Business Wire)
Mar-15-22 07:00AM	Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22 (Business Wire) +8.57%
Mar-08-22 04:30PM	Aura Biosciences to Present Preclinical Data Highlighting AU011s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting (Business Wire) +5.81%
Feb-28-22 07:00AM	Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference (Business Wire)
Feb-14-22 05:00PM	Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium (Business Wire) +13.09%
Feb-09-22 08:00AM	Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference (Business Wire)
Feb-03-22 01:38PM	Medicxi Ventures Management (Jersey) Ltd Buys Aura Biosciences Inc (GuruFocus.com)
Jan-29-22 07:52AM	What Percentage Of Aura Biosciences, Inc. (NASDAQ:AURA) Shares Do Insiders Own? (Simply Wall St.)
Nov-24-21 04:05PM	Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +11.36% +13.16%
Nov-23-21 04:05PM	Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference (Business Wire) -9.43%
Nov-15-21 11:00AM	Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting (Business Wire) +18.35%
Oct-28-21 09:39PM	Aura Biosciences Announces Pricing of Initial Public Offering (Business Wire)

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnson David Michael	Director	May 16 '25	Buy	4.90	20,000	98,000	166,167	May 20 05:43 PM
Gibney Anthony S	See Remarks	May 16 '25	Buy	4.90	50,000	245,000	58,452	May 20 05:34 PM
Gibney Anthony S	See Remarks	May 16 '25	Sale	5.15	1,519	7,823	56,933	May 20 05:34 PM
Gibney Anthony	Officer	May 16 '25	Proposed Sale	5.15	1,519	7,823		May 16 04:57 PM
Elazzouzi Amy	Officer	Apr 16 '25	Proposed Sale	5.49	897	4,925		Apr 16 08:37 PM
Kilroy Conor	Officer	Apr 16 '25	Proposed Sale	5.49	7,162	39,319		Apr 16 08:37 PM
Elazzouzi Amy	Senior Vice President, Finance	Apr 16 '25	Sale	5.49	897	4,925	81,381	Apr 16 08:36 PM
Kilroy Conor	See Remarks	Apr 16 '25	Sale	5.49	7,162	39,319	179,313	Apr 16 08:36 PM
Plavsic Mark	Officer	Feb 18 '25	Proposed Sale	7.75	2,151	16,670		Feb 18 07:32 PM
Hopkins Janet Jill	Officer	Feb 18 '25	Proposed Sale	7.75	2,534	19,639		Feb 18 07:32 PM
Elazzouzi Amy	Officer	Feb 18 '25	Proposed Sale	7.75	1,404	10,881		Feb 18 07:32 PM
de los Pinos Elisabet	Officer	Feb 18 '25	Proposed Sale	7.75	20,221	156,796		Feb 18 07:31 PM
Plavsic Mark	Chief Technology Officer	Feb 18 '25	Sale	7.75	2,151	16,670	209,456	Feb 18 07:31 PM
Elazzouzi Amy	Senior Vice President, Finance	Feb 18 '25	Sale	7.75	1,404	10,881	82,278	Feb 18 07:31 PM
Hopkins Janet Jill	Chief Medical Officer	Feb 18 '25	Sale	7.75	2,534	19,638	269,794	Feb 18 07:30 PM
de los Pinos Elisabet	See Remarks	Feb 18 '25	Sale	7.75	20,221	156,796	482,440	Feb 18 07:30 PM
de los Pinos Elisabet	Officer	Jan 21 '25	Proposed Sale	7.67	15,955	122,381		Jan 21 09:10 PM
Elazzouzi Amy	Officer	Jan 21 '25	Proposed Sale	7.67	1,001	7,679		Jan 21 09:10 PM
de los Pinos Elisabet	See Remarks	Jan 21 '25	Sale	7.67	15,955	122,381	304,692	Jan 21 09:09 PM
Elazzouzi Amy	Vice President, Finance	Jan 21 '25	Sale	7.67	1,001	7,679	38,442	Jan 21 09:09 PM
Hopkins Janet Jill	Chief Medical Officer	Nov 18 '24	Sale	9.36	11,822	110,663	151,693	Nov 18 09:06 PM
Janet Jill Hopkins	Officer	Nov 18 '24	Proposed Sale	9.36	11,822	110,663		Nov 18 07:32 PM
Amy Elazzouzi	Officer	Oct 29 '24	Proposed Sale	10.74	553	5,938		Oct 29 08:38 PM
Elisabet de los Pinos	Officer	Oct 29 '24	Proposed Sale	10.74	9,200	98,788		Oct 29 08:33 PM
Julie B. Feder	Former Officer	Oct 29 '24	Proposed Sale	10.74	3,249	34,889		Oct 29 08:33 PM
de los Pinos Elisabet	See Remarks	Oct 29 '24	Sale	10.74	9,200	98,788	320,647	Oct 29 08:28 PM
Elazzouzi Amy	Vice President, Finance	Oct 29 '24	Sale	10.74	553	5,938	39,443	Oct 29 08:23 PM
Feder Julie B	Chief Financial Officer	Oct 18 '24	Option Exercise	3.44	25,131	86,532	159,407	Oct 21 06:23 PM
Feder Julie B	Chief Financial Officer	Oct 18 '24	Sale	12.03	25,131	302,361	134,276	Oct 21 06:23 PM
de los Pinos Elisabet	See Remarks	Oct 18 '24	Option Exercise	2.74	24,992	68,478	354,839	Oct 18 08:08 PM
de los Pinos Elisabet	See Remarks	Oct 18 '24	Sale	12.04	24,992	300,839	329,847	Oct 18 08:08 PM
JULIE FEDER	Officer	Oct 18 '24	Proposed Sale	10.29	25,131	258,598		Oct 18 04:21 PM
ELISABET DE LOS PINOS	Director	Oct 18 '24	Proposed Sale	10.29	24,992	257,168		Oct 18 04:21 PM
Plavsic Mark	Chief Technology Officer	Oct 16 '24	Sale	9.85	7,383	72,723	121,132	Oct 16 09:25 PM
Plavsic Mark	Officer	Oct 16 '24	Proposed Sale	9.85	7,383	72,723		Oct 16 09:22 PM
de los Pinos Elisabet	See Remarks	Sep 27 '24	Option Exercise	5.76	5,474	31,530	329,847	Oct 01 05:08 PM

Open in Screener

CLSD

Clearside Biomedical Inc

May 23 • 04:00PM ET

0.8630

Dollar change -0.0026
Percentage change -0.30	%

Healthcare • Biotechnology • USA • NASD

CLSD Clearside Biomedical Inc daily Stock Chart

Peers: EYPT VKTX OCUL TVRD ALDX RIGL IRD AKBA BYSI

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.41	Insider Own	21.04%	Shs Outstand	77.27M	Perf Week	-1.81%
Market Cap	67.06M	Forward P/E	-	EPS next Y	-0.61	Insider Trans	0.09%	Shs Float	61.36M	Perf Month	1.71%
Income	-30.81M	PEG	-	EPS next Q	-0.10	Inst Own	13.29%	Short Float	0.41%	Perf Quarter	-1.93%
Sales	3.76M	P/S	17.84	EPS this Y	13.37%	Inst Trans	-5.34%	Short Ratio	1.41	Perf Half Y	-16.21%
Book/sh	-0.59	P/B	-	EPS next Y	-49.82%	ROA	-103.03%	Short Interest	0.25M	Perf Year	-42.08%
Cash/sh	0.18	P/C	4.92	EPS next 5Y	-2.08%	ROE	-	52W Range	0.70 - 1.65	Perf YTD	-9.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.40%	ROI	-396.49%	52W High	-47.70%	Beta	2.12
Dividend TTM	-	Quick Ratio	3.19	Sales past 5Y	176.51%	Gross Margin	81.93%	52W Low	23.27%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	3.19	EPS Y/Y TTM	24.92%	Oper. Margin	-687.51%	RSI (14)	49.54	Volatility	2.68% 2.33%
Employees	32	Debt/Eq	-	Sales Y/Y TTM	-55.47%	Profit Margin	-818.57%	Recom	1.00	Target Price	5.43
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	36.52%	Payout	-	Rel Volume	0.73	Prev Close	0.87
Sales Surprise	1166.99%	EPS Surprise	-1.85%	Sales Q/Q	913.04%	Earnings	May 14 AMC	Avg Volume	177.18K	Price	0.86
SMA20	-0.20%	SMA50	-1.96%	SMA200	-14.48%	Trades		Volume	129,302	Change	-0.30%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-24	Initiated	Chardan Capital Markets	Buy	$6
Jun-25-24	Initiated	Oppenheimer	Outperform	$5
Dec-15-21	Resumed	Wedbush	Outperform	$19 → $9
Jul-29-21	Initiated	H.C. Wainwright	Buy	$10
May-13-20	Initiated	ROTH Capital	Buy	$8
Aug-09-19	Downgrade	Needham	Buy → Hold
Nov-05-18	Downgrade	Stifel	Buy → Hold
Nov-05-18	Downgrade	JP Morgan	Overweight → Underweight
Nov-05-18	Downgrade	Cowen	Outperform → Market Perform
Mar-06-18	Reiterated	Needham	Buy	$18 → $22
May-25-17	Initiated	JMP Securities	Mkt Outperform	$21
Feb-24-17	Initiated	JP Morgan	Overweight	$19
Nov-10-16	Reiterated	Needham	Buy	$16 → $24
Oct-24-16	Reiterated	Stifel	Buy	$13 → $23

Show Previous Ratings

May-21-25 07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum (GlobeNewswire)
May-14-25 05:35PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.09%
04:05PM	Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-13-25 05:10PM	Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
09:46AM	Clearside Biomedical Inc (CLSD) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
07:05AM	Loading…
May-09-25 07:05AM	Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting (GlobeNewswire)
May-08-25 07:05AM	Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 (GlobeNewswire)
May-06-25 06:30PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 10:01AM	Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know (Zacks)
07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire)
Apr-01-25 09:00PM	Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 08:31PM	Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript (Seeking Alpha) -7.77%
05:20PM	Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:05AM	Loading…
Mar-24-25 07:05AM	Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting (GlobeNewswire)
Mar-20-25 07:05AM	Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit (GlobeNewswire)
Mar-12-25 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 (GlobeNewswire)
Mar-06-25 07:05AM	Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD (GlobeNewswire) +14.82%
Feb-20-25 07:05AM	Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS for Regulatory Review in China for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Feb-10-25 07:05AM	Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting (GlobeNewswire)
Feb-04-25 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference (GlobeNewswire)
Jan-28-25 07:05AM	Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program (GlobeNewswire)
Jan-22-25 07:05AM	Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore (GlobeNewswire)
Dec-20-24 07:16AM	Clearside announces publication of insights on drug development, regulation (TipRanks) -6.20%
05:29AM	Analyst Sees 500% Upside for This Pharmaceutical Penny Stock (GuruFocus.com)
Dec-19-24 07:05AM	Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye (GlobeNewswire)
Dec-12-24 09:55AM	Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Nov-25-24 07:05AM	Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States (GlobeNewswire)
Nov-15-24 12:00PM	All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy (Zacks) -5.71%
02:17AM	Loading…
Nov-13-24 02:17AM	Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... (GuruFocus.com)
Nov-12-24 06:05PM	Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-24 07:23AM	Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-08-24 03:56AM	Santen, Arctic Vision sign deal for ARVN001 to treat UME (Pharmaceutical Technology)
Nov-07-24 09:05AM	Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Nov-06-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:05AM	Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors (GlobeNewswire)
Oct-31-24 07:05AM	Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-22-24 07:05AM	Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting (GlobeNewswire) -10.23%
Oct-10-24 08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-09-24 10:22AM	Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study (Benzinga) -11.49%
06:30AM	Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes (GlobeNewswire)
Aug-27-24 07:05AM	Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Aug-15-24 09:35AM	After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD) (Zacks)
Aug-12-24 05:25PM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-24 07:05AM	Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-05-24 10:00AM	Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Aug-01-24 07:05AM	Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 (GlobeNewswire)
Jul-29-24 04:05PM	Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS for Suprachoroidal Use in Uveitic Macular Edema Patients in China (GlobeNewswire)
Jul-22-24 12:00PM	Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET (GlobeNewswire)
Jul-11-24 07:05AM	Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board (GlobeNewswire)
Jun-27-24 07:05AM	Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery (GlobeNewswire) +5.79%
Jun-12-24 07:05AM	Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting (GlobeNewswire)
May-21-24 07:05AM	Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS ) Injection in Leading Peer-Reviewed Industry Journal, RETINA (GlobeNewswire) +12.03%
May-13-24 08:20AM	HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating (MT Newswires)
May-10-24 02:15PM	Q1 2024 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents) -7.41%
11:56AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:55PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +6.30%
04:05PM	Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 04:15PM	Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-30-24 07:05AM	Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-16-24 07:05AM	Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors (GlobeNewswire) -10.85%
Apr-02-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -11.39%
Mar-18-24 07:05AM	Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer (GlobeNewswire) -8.77%
Mar-13-24 08:30AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:38AM	Q4 2023 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 05:35PM	Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ... (GuruFocus.com) -18.81%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 02:25PM	These 2 Strong Buy Penny Stocks Could Surge Over 200%, Say Analysts (TipRanks) +8.63%
Feb-29-24 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 (GlobeNewswire)
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-07-24 08:00AM	Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering (GlobeNewswire)
Dec-14-23 07:05AM	Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Nov-14-23 09:11AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:05PM	Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-23 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference (GlobeNewswire) -9.65%
Nov-07-23 04:20PM	Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector (GlobeNewswire) +19.39%
Nov-02-23 07:05AM	Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Nov-01-23 07:05AM	Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD (GlobeNewswire) +5.30%
Oct-31-23 07:05AM	Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023 (GlobeNewswire) +5.17%
Oct-26-23 12:24AM	3 Cheap Stocks to Buy Under $1 in October 2023 (InvestorPlace) -5.28%
Oct-16-23 07:05AM	Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 09:00AM	Clearside Biomedical Announces Advancement of XIPERE in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China (GlobeNewswire)
Oct-03-23 04:35PM	Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit (GlobeNewswire)
Sep-19-23 07:05AM	Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-14-23 04:05PM	Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.60%
Aug-02-23 04:30PM	Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023 (GlobeNewswire) -5.26%
Aug-01-23 07:05AM	Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023 (GlobeNewswire)
Jul-31-23 07:05AM	Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting (GlobeNewswire)
Jul-20-23 07:05AM	Clearside Biomedicals Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings (GlobeNewswire)
Jul-11-23 04:05PM	Clearside Biomedical CEO George Lasezkay to Present at the SHARE Series Investor Event on Monday, July 17, 2023 (GlobeNewswire)
Jul-10-23 07:05AM	Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Jun-29-23 09:50AM	We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate (Simply Wall St.)
Jun-01-23 07:05AM	Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
May-11-23 08:25AM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.90%
07:05AM	Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:30PM	Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%

Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. Its SCS microinjector enables a simple, repeatable, in-office procedure to deliver treatments directly to the macula, retina, or choroid, potentially helping to preserve and improve vision in patients with serious eye diseases. Its pipeline includes CLS-AX, an Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thorp Clay	Director	Feb 24 '25	Buy	0.92	15,000	13,800	176,141	Feb 24 05:52 PM
Chong Ngai Hang Victor	Chief Medical Officer	Nov 01 '24	Buy	1.00	36,500	36,500	100,000	Nov 04 04:15 PM
Chong Ngai Hang Victor	Chief Medical Officer	Jun 24 '24	Buy	1.06	23,500	24,910	63,500	Jun 24 04:38 PM

AURA

Aura Biosciences Inc

CLSD

Clearside Biomedical Inc

Upgrade your FINVIZ experience